FLUMAZENIL
Clinical safety rating: safe
Animal studies have demonstrated safety
Competitive antagonist at GABA-A receptor benzodiazepine binding site, reversing CNS depression.
| Metabolism | Hepatic metabolism via microsomal oxidation; primary metabolite is N-desmethylflumazenil. |
| Excretion | Primarily hepatic metabolism to inactive metabolites, with renal excretion of metabolites accounting for >90% of the dose; less than 1% unchanged drug excreted renally; fecal excretion negligible. |
| Half-life | Terminal elimination half-life is 2.5-5 hours (mean ~3.5 h) in adults; prolonged to up to 25-30 hours in hepatic impairment; clinical context: single dose reverses benzodiazepine effects for 1-2 hours, but resedation may occur due to shorter half-life compared to long-acting benzodiazepines. |
| Protein binding | Approximately 50% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.9-1.2 L/kg (mean 1.0 L/kg), indicating distribution into total body water with moderate tissue binding. |
| Bioavailability | IV: 100%; Oral: not used due to <5% bioavailability (extensive first-pass metabolism); IM: ~100% (bioequivalent to IV). |
| Onset of Action | IV: 1-2 minutes (peak effect at 6-10 minutes); IM: 10-20 minutes; oral: not used clinically due to extensive first-pass metabolism. |
| Duration of Action | IV: 1-2 hours (antagonism of sedation); duration may be shorter than that of long-acting benzodiazepines (e.g., diazepam), necessitating repeat doses or infusion; clinical note: resedation can occur if benzodiazepine persists. |
| Molecular Weight | 303.3 |
Initial dose 0.2 mg IV over 15 seconds; if desired level of consciousness not achieved after 45 seconds, repeat 0.2 mg IV every 60 seconds up to a maximum total dose of 1 mg (usual cumulative dose 0.6-1 mg). For resedation, repeat doses at 20-minute intervals; maximum 3 mg/hour.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose adjustment required; flumazenil is primarily hepatically metabolized with minimal renal excretion. |
| Liver impairment | Child-Pugh A: No adjustment necessary. Child-Pugh B or C: Reduce initial dose to 0.1 mg IV over 15 seconds; repeat 0.1 mg at 60-second intervals up to maximum total dose 0.5 mg. Reduce maximum hourly rate to 1.5 mg/hour. |
| Pediatric use | Children >1 year: Initial dose 0.01 mg/kg (maximum 0.2 mg) IV over 15 seconds; if desired response not achieved after 45 seconds, repeat 0.01 mg/kg (maximum 0.2 mg) every 60 seconds up to a maximum total dose of 0.05 mg/kg or 1 mg (whichever is lower). Resedation: repeat doses at 20-minute intervals; maximum 0.05 mg/kg/hour or 1 mg/hour (whichever is lower). |
| Geriatric use | Consider lower initial dose (0.1 mg IV) and slower titration due to increased sensitivity and prolonged clearance. Maximum total dose 1 mg. |
| 1st trimester | Limited human data; animal studies suggest risk. Use only if potential benefit justifies risk. |
| 2nd trimester | Limited human data; consider risk-benefit. May be used for reversal of benzodiazepine sedation during procedures. |
| 3rd trimester | Use near term may cause neonatal withdrawal or hypotonia. Avoid unless for maternal seizure management. |
Clinical note
Can precipitate acute withdrawal in patients dependent on benzodiazepines Seizures may occur especially in patients on long-term benzodiazepines.
| Placental transfer | Crosses placenta; achieves fetal concentrations similar to maternal levels. |
| Breastfeeding | Excreted into breast milk in low amounts. Not expected to cause adverse effects in nursing infants. Caution with high maternal doses. |
■ FDA Black Box Warning
None.
| Common Effects | Dizziness |
| Serious Effects |
Known hypersensitivity to flumazenil or benzodiazepinesSevere hepatic impairmentEpilepsy or history of seizures (relative, but absolute if benzodiazepine withdrawal seizure risk)
| Precautions | May precipitate acute withdrawal in benzodiazepine-dependent patients; risk of seizures, especially in mixed overdose or epilepsy; monitor for re-sedation due to short half-life (t1/2 ~1 hr). |
| Food/Dietary | No known food interactions. Avoid alcohol as it may increase sedation or withdrawal symptoms. |
Loading safety data…
| Lactation Rating |
| L2 (Probably Compatible) |
| Teratogenic Risk | Flumazenil is classified as FDA Pregnancy Category C. Animal studies have shown an increased incidence of fetal skeletal anomalies at doses 2-4 times the human dose. There are no adequate and well-controlled studies in pregnant women. Potential fetal risks include skeletal malformations and central nervous system effects, particularly during the first trimester. Use only if potential benefit justifies potential risk to the fetus. |
| Fetal Monitoring | Monitor maternal vital signs (heart rate, blood pressure, respiratory rate) and level of consciousness. Fetal heart rate monitoring should be considered during prolonged use or high doses. Observe for maternal withdrawal symptoms or seizures, especially in benzodiazepine-dependent patients. |
| Fertility Effects | No specific data on flumazenil's effect on fertility in humans. Animal studies have not reported impaired fertility. Theoretical risk of hormonal disruption is low due to short half-life and mechanism of action. |
| Clinical Pearls | Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation. Administer slowly intravenously over 15-30 seconds to prevent acute withdrawal in chronic benzodiazepine users. Onset is 1-2 minutes; peak effect at 6-10 minutes. Duration is 1-2 hours, shorter than most benzodiazepines, so resedation may occur. Do not use in patients with suspected tricyclic antidepressant overdose or seizure history. Monitor for seizures, especially in mixed overdoses. |
| Patient Advice | Flumazenil reverses the effects of benzodiazepines used for sedation or overdose. · You may experience anxiety, palpitations, or agitation as the drug wears off. · Seizures are a rare but serious risk, especially if you have a history of seizures or chronic benzodiazepine use. · Do not drive or operate machinery for at least 24 hours after administration. · Report any signs of withdrawal such as confusion, hallucinations, or rapid heartbeat. |